Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Depreciation & Amortization (CF) (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $12225.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 182.07% to $12225.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $33604.0, a 312.22% increase, with the full-year FY2024 number at $11726.0, down 44.59% from a year prior.
  • Depreciation & Amortization (CF) was $12225.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $9236.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $12225.0 in Q3 2025 to a low of $407.0 in Q1 2024.
  • A 4-year average of $5757.3 and a median of $6694.0 in 2025 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 94.1% in 2024, then soared 1544.72% in 2025.
  • 60 Degrees Pharmaceuticals' Depreciation & Amortization (CF) stood at $6901.0 in 2022, then tumbled by 72.83% to $1875.0 in 2023, then surged by 190.61% to $5449.0 in 2024, then soared by 124.35% to $12225.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Depreciation & Amortization (CF) are $12225.0 (Q3 2025), $9236.0 (Q2 2025), and $6694.0 (Q1 2025).